Phase I trial of gemcitabine and Wilms' tumor 1 peptide vaccine combination therapy in patients with advanced pancreatic or biliary tract cancer
| Autor: | Chigusa Morizane, Y. Morita-Hoshi, Yuji Heike, H. Ueno, Y. Yamaki, Takako Wakeda, M. Kaida, A. Soeda, Shunsuke Kondo, Takuji Okusaka |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Combination therapy business.industry medicine.medical_treatment Wilms' tumor medicine.disease Gastroenterology Gemcitabine Cancer immunotherapy Pancreatic cancer Internal medicine Peptide vaccine medicine Gallbladder cancer business Adjuvant medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 28:e13049-e13049 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2010.28.15_suppl.e13049 |
| Popis: | e13049 Background: WT1 is expressed in various kinds of cancers and serves as a potent antigen for cancer immunotherapy. Methods: We performed a clinical phase I trial of gemcitabine (GEM) and WT1 vaccine combination therapy for advanced pancreatic cancer or biliary tract cancer. Patients with HLA-A 0201, HLA-A 0206, and/or HLA-A 2402 positive inoperable advanced pancreatic or biliary tract cancer, who has not received GEM previously were eligible. Six doses of GEM and 4 doses of WT1 vaccination were administered with the following schedule in 2 months: GEM (1000 mg/m2) was administered intravenously on days 1, 8, and 15 with 1-week rest. WT1 peptide (1 mg or 3 mg) in Montanide adjuvant was injected intradermally on day 8 and day 22. Results: Between November 2007 and September 2009, 25 patients (13 male, 12 female) were enrolled in this study. Nine patients had inoperable advanced pancreatic cancer, 8 had gallbladder cancer, 4 had intrahepatic bile duct cancer, and 4 had extrahepatic bile duct cancer. Ou... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|